[go: up one dir, main page]

PE20161218A1 - (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 - Google Patents

(2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1

Info

Publication number
PE20161218A1
PE20161218A1 PE2016001236A PE2016001236A PE20161218A1 PE 20161218 A1 PE20161218 A1 PE 20161218A1 PE 2016001236 A PE2016001236 A PE 2016001236A PE 2016001236 A PE2016001236 A PE 2016001236A PE 20161218 A1 PE20161218 A1 PE 20161218A1
Authority
PE
Peru
Prior art keywords
oxazepan
carboxamides
phenylethyl
cyano
cyane
Prior art date
Application number
PE2016001236A
Other languages
English (en)
Inventor
Carl-Johan Aurell
Stephen Connolly
Kevin James Doyle
Graham Peter Jones
Hans Roland Lonn
David Wyn Watson
Nicholas John Palmer
Karlsson Staffan Po
John Fritiof Ponten
Steven Swallow
De Poel Amanda Jane Van
Jaqueline Anne Macritchie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161218(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20161218A1 publication Critical patent/PE20161218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se refiere a un compuesto derivado de (2S)-N-[(1S)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas de formula I o sales farmaceuticamente aceptables, donde: R1 es (a); R2 es hidrogeno, F, Cl, Br, entre otros; R3 es hidrogeno, F, Cl, CN, entre otros; o R1 es (b), (c), entre otros, donde: X es O, S o CF2; Y es O o S; R6 es alquilo C1-C3 opcionalmente sustituido por 1, 2 o 3 F, OH, entre otros; R7 es F, Cl o CH3. Son compuestos preferidos: (2S)-N-[(1S)-1-Ciano-2-(4'-cianobifenil-4-il)etil]-1,4-oxazepan-2-carboxamida; (2S)-N-{(1S)-1-Ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepan-2-carboxamida; entre otros. Tambien se refiere a un metodo de tratamiento y a una composicion farmaceutica. Dichos compuestos inhiben la actividad de la dipeptidilpeptidasa (DPP1), siendo utiles en el tratamiento de enfermedades respiratorias tales como asma, enfermedad pulmonar obstructiva cronica (COPD), entre otros
PE2016001236A 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 PE20161218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
PE20161218A1 true PE20161218A1 (es) 2016-11-27

Family

ID=52432834

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001236A PE20161218A1 (es) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1

Country Status (39)

Country Link
US (18) US9522894B2 (es)
EP (4) EP3744714B1 (es)
JP (7) JP6469711B2 (es)
KR (1) KR102417684B1 (es)
CN (2) CN110483492B (es)
AP (1) AP2016009322A0 (es)
AR (1) AR099177A1 (es)
AU (4) AU2015208932C1 (es)
BR (1) BR112016016224B1 (es)
CA (1) CA2935625C (es)
CL (1) CL2016001889A1 (es)
CR (1) CR20160327A (es)
CY (2) CY1120049T1 (es)
DK (3) DK3744714T3 (es)
DO (1) DOP2016000175A (es)
EA (1) EA032794B1 (es)
ES (3) ES3018635T3 (es)
FI (1) FI3744714T3 (es)
HK (1) HK1225730B (es)
HR (3) HRP20250302T1 (es)
HU (3) HUE070606T2 (es)
IL (3) IL246614B (es)
LT (3) LT3097086T (es)
MX (1) MX368840B (es)
MY (1) MY194850A (es)
NO (1) NO2699580T3 (es)
NZ (2) NZ722063A (es)
PE (1) PE20161218A1 (es)
PH (1) PH12016501439B1 (es)
PL (3) PL3744714T3 (es)
PT (3) PT3744714T (es)
RS (3) RS56919B1 (es)
SG (2) SG10201701056QA (es)
SI (3) SI3744714T1 (es)
SM (3) SMT202000433T1 (es)
TW (1) TWI690517B (es)
UY (1) UY35963A (es)
WO (1) WO2015110826A1 (es)
ZA (2) ZA201605856B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (es) 2014-01-24 2018-02-24
KR20230054480A (ko) * 2016-07-29 2023-04-24 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
EP3749326A4 (en) * 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
EP3758708B1 (en) 2018-03-01 2024-11-27 AstraZeneca AB Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
KR20210032439A (ko) * 2018-07-17 2021-03-24 인스메드 인코포레이티드 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
WO2021079300A1 (en) * 2019-10-23 2021-04-29 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating chronic obstructive pulmonary diseases (copd)
JP2023535332A (ja) * 2020-07-20 2023-08-17 インスメッド インコーポレイテッド 好中球セリンプロテアーゼを抽出するおよびジペプチジルペプチダーゼ１媒介性病態を治療するための方法
SMT202400510T1 (it) 2020-08-26 2025-01-14 Haisco Pharmaceuticals Pte Ltd Derivato di nitrile che agisce come inibitore di dipeptidil peptidasi 1 e suo uso
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
AU2021391452A1 (en) 2020-12-04 2023-06-29 Reistone Biopharma Company Limited Small molecule inhibitor of cathepsin c and medicinal use thereof
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN116783189A (zh) * 2021-02-05 2023-09-19 南京明德新药研发有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
KR20240004691A (ko) * 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
EP4423071A4 (en) * 2021-10-29 2025-08-13 Insmed Inc USES OF CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINO-SINUSITIS
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
CN118475575A (zh) * 2022-01-11 2024-08-09 上海壹典医药科技开发有限公司 一种肽基腈类化合物及其应用
AU2023221393A1 (en) * 2022-02-16 2024-08-15 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
EP4484424A1 (en) * 2022-02-22 2025-01-01 Haisco Pharmaceuticals Pte. Ltd. Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
IL314855A (en) * 2022-02-22 2024-10-01 Haisco Pharmaceuticals Pte Ltd Preparation method of nitrogen-containing heterocyclic compound
WO2023160542A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
WO2023236877A1 (zh) * 2022-06-07 2023-12-14 瑞石生物医药有限公司 苯并[c]色满化合物的可药用盐、其多晶型及用途
CA3258114A1 (en) * 2022-06-07 2025-03-20 Reistone Biopharma Company Ltd BENZO[C]CHROMANE COMPOUND POLYMORPH, ITS PREPARATION PROCESS AND ITS USE
KR20250022023A (ko) 2022-06-13 2025-02-14 알리벡시스 가부시키가이샤 아자사이클로알킬카보닐 환상 아민 화합물
EP4551554A1 (en) 2022-07-06 2025-05-14 Chiesi Farmaceutici S.p.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
CN119948034A (zh) * 2022-10-26 2025-05-06 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
WO2024148308A1 (en) * 2023-01-06 2024-07-11 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
CN120693326A (zh) * 2023-02-15 2025-09-23 英斯梅德股份有限公司 某些1，4-氧杂氮杂环庚烷-2-甲酰胺作为dpp1抑制剂的用途
AU2024241242A1 (en) * 2023-03-23 2025-11-06 Haisco Pharmaceuticals Pte. Ltd. Pharmaceutical composition containing dipeptidyl peptidase small molecule inhibitor
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
AU3815102A (en) 2000-09-08 2002-03-22 Prozymex As Dipeptidyl peptidase I crystal structure and its uses
CA2424964C (en) * 2000-10-06 2007-12-04 Tanabe Seiyaku Co., Ltd. Nitrogen-containing 5-membered ring compound
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
RU2004120784A (ru) 2001-12-04 2005-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Замещенные 2-аминоциклоалканкарбоксамиды и их применение в качестве ингибиторов цистеиновой протеазы
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP1975153A3 (en) 2003-05-30 2010-03-31 Prozymex A/S Protease inhibitors
EP1638925A1 (en) 2003-06-18 2006-03-29 Prozymex A/S Protease inhibitors
SG152226A1 (en) 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP2017620A3 (en) 2004-04-28 2009-04-22 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
KR100875299B1 (ko) 2004-06-29 2008-12-23 니코메드 덴마크 에이피에스 비수용성 약물의 속방성 약학 조성물 제조 방법 및 상기방법에 의하여 얻어지는 약학 조성물
EP1778224B1 (en) 2004-07-19 2014-03-26 The Johns-Hopkins University Flt3 inhibitors for immune suppression
CN105288630A (zh) 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
JP2009500347A (ja) 2005-06-30 2009-01-08 アムジエン・インコーポレーテツド ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用
EP2139887A2 (en) 2007-03-07 2010-01-06 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
AU2008305591A1 (en) 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
WO2009074829A1 (en) * 2007-12-12 2009-06-18 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
WO2010114405A2 (en) 2009-04-01 2010-10-07 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2010128324A1 (en) * 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
BR112013020510A2 (pt) 2011-02-11 2016-07-12 Glaxosmithkline Ip Dev Ltd inibidores de catepsina c
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
EP2817310B1 (en) 2012-02-21 2018-03-21 Merck Patent GmbH 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
ES2644965T3 (es) 2012-04-17 2017-12-01 Astellas Pharma Inc. Compuesto heterocíclico aromático bicíclico nitrogenado
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140081A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
AP2015008601A0 (en) 2013-03-14 2015-07-31 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
JP6441830B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
JP6441831B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
US10670594B2 (en) 2013-08-22 2020-06-02 Emory University Devices and methods related to airway inflammation
WO2015032943A1 (en) 2013-09-09 2015-03-12 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (es) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CN106456552A (zh) 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
KR102657132B1 (ko) 2014-05-15 2024-04-12 인스메드 인코포레이티드 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
CN107075557B (zh) 2014-05-30 2021-07-06 香港大学 使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
NZ728684A (en) 2014-09-12 2022-09-30 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
CN107108592B (zh) 2014-11-14 2021-01-29 勃林格殷格翰国际有限公司 吗啉和1,4-氧氮杂环庚烷酰胺作为抑生长素受体亚型4(sstr4)激动剂
CA2978234C (en) 2015-03-05 2023-05-02 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
KR20230054480A (ko) 2016-07-29 2023-04-24 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
EP3749326A4 (en) * 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
EP3758708B1 (en) * 2018-03-01 2024-11-27 AstraZeneca AB Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
KR20210032439A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
JP7085073B2 (ja) 2019-04-17 2022-06-15 アゾーラ セラピューティクス，インコーポレイテッド 炎症性皮膚疾患を処置するための局所組成物及び方法
KR20220026538A (ko) 2019-06-05 2022-03-04 에모리 유니버시티 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
KR20240004691A (ko) 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
EP4423071A4 (en) 2021-10-29 2025-08-13 Insmed Inc USES OF CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINO-SINUSITIS
AU2023221393A1 (en) 2022-02-16 2024-08-15 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Also Published As

Publication number Publication date
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
MY194850A (en) 2022-12-19
ZA201800431B (en) 2019-09-25
EA201691375A1 (ru) 2017-01-30
CR20160327A (es) 2016-10-20
IL265611A (en) 2019-05-30
RS66709B1 (sr) 2025-05-30
US20230028726A1 (en) 2023-01-26
JP7714823B2 (ja) 2025-07-29
HRP20250302T1 (hr) 2025-04-25
CY1123391T1 (el) 2021-12-31
CY1120049T1 (el) 2018-12-12
US20230116721A1 (en) 2023-04-13
JP7336563B2 (ja) 2023-08-31
US11814359B2 (en) 2023-11-14
JP2025157389A (ja) 2025-10-15
ES2658516T3 (es) 2018-03-12
EP3744714B1 (en) 2025-01-15
PL3323814T3 (pl) 2020-10-19
SMT202000433T1 (it) 2020-09-10
AU2019202675A1 (en) 2019-05-16
AR099177A1 (es) 2016-07-06
DK3097086T3 (en) 2018-02-05
US20210238152A1 (en) 2021-08-05
US11680049B2 (en) 2023-06-20
BR112016016224B1 (pt) 2023-02-23
MX2016009349A (es) 2016-10-13
US9815805B2 (en) 2017-11-14
AU2017200338A1 (en) 2017-02-02
KR20160111470A (ko) 2016-09-26
EP3323814B1 (en) 2020-05-13
US20150210655A1 (en) 2015-07-30
DK3323814T3 (da) 2020-08-03
HK1255870A1 (en) 2019-08-30
HUE070606T2 (hu) 2025-06-28
US20240336582A1 (en) 2024-10-10
AU2018202956B2 (en) 2019-05-09
NO2699580T3 (es) 2018-02-24
US20230062646A1 (en) 2023-03-02
AU2015208932B8 (en) 2017-03-09
ZA201605856B (en) 2020-02-26
US20230033573A1 (en) 2023-02-02
HUE052421T2 (hu) 2021-04-28
US20180251436A1 (en) 2018-09-06
SI3744714T1 (sl) 2025-05-30
CN105980367A (zh) 2016-09-28
HK1225730B (en) 2017-09-15
US11655223B2 (en) 2023-05-23
US11673871B2 (en) 2023-06-13
CN105980367B (zh) 2019-08-23
US20230069044A1 (en) 2023-03-02
US9522894B2 (en) 2016-12-20
US10287258B2 (en) 2019-05-14
SI3097086T1 (en) 2018-04-30
RS60639B1 (sr) 2020-09-30
HRP20201147T1 (hr) 2020-12-11
CN110483492A (zh) 2019-11-22
LT3744714T (lt) 2025-04-10
US20240132455A1 (en) 2024-04-25
US11117874B2 (en) 2021-09-14
SG11201606052TA (en) 2016-08-30
US20200017455A1 (en) 2020-01-16
US20230115170A1 (en) 2023-04-13
US10669245B2 (en) 2020-06-02
CA2935625A1 (en) 2015-07-30
CA2935625C (en) 2022-10-18
LT3097086T (lt) 2018-02-26
BR112016016224A2 (es) 2017-08-08
PT3744714T (pt) 2025-04-07
EP3097086A1 (en) 2016-11-30
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
JP2025072423A (ja) 2025-05-09
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
SG10201701056QA (en) 2017-03-30
EP4548972A2 (en) 2025-05-07
US20230278969A1 (en) 2023-09-07
MX368840B (es) 2019-10-18
EA032794B1 (ru) 2019-07-31
CN110483492B (zh) 2023-07-21
EP3744714A1 (en) 2020-12-02
JP2022096662A (ja) 2022-06-29
PL3097086T3 (pl) 2018-04-30
AU2015208932B2 (en) 2017-02-16
KR102417684B1 (ko) 2022-07-05
AP2016009322A0 (en) 2016-07-31
US20170057938A1 (en) 2017-03-02
US20230250071A1 (en) 2023-08-10
AU2015208932C1 (en) 2017-05-25
JP6469711B2 (ja) 2019-02-13
US11673872B2 (en) 2023-06-13
JP7157791B2 (ja) 2022-10-20
SMT201800058T1 (it) 2018-03-08
US11655224B2 (en) 2023-05-23
TW201612167A (en) 2016-04-01
AU2015208932A8 (en) 2017-03-09
DK3744714T3 (da) 2025-04-07
ES3018635T3 (es) 2025-05-16
HRP20180116T1 (hr) 2018-03-23
JP6804570B2 (ja) 2020-12-23
AU2015208932A1 (en) 2016-07-28
EP4548972A3 (en) 2025-06-25
US20230025351A1 (en) 2023-01-26
AU2018202956A1 (en) 2018-05-17
JP7628587B2 (ja) 2025-02-10
US11655221B2 (en) 2023-05-23
IL252836A0 (en) 2017-08-31
TWI690517B (zh) 2020-04-11
AU2017200338B2 (en) 2018-03-01
JP2021046423A (ja) 2021-03-25
JP2023156479A (ja) 2023-10-24
JP2017503832A (ja) 2017-02-02
SMT202500137T1 (it) 2025-05-12
EP3097086B1 (en) 2017-12-13
WO2015110826A1 (en) 2015-07-30
PH12016501439A1 (en) 2017-02-06
EP3323814A1 (en) 2018-05-23
SI3323814T1 (sl) 2020-10-30
US20200247765A1 (en) 2020-08-06
DOP2016000175A (es) 2016-08-15
JP2019070029A (ja) 2019-05-09
PL3744714T3 (pl) 2025-09-08
CL2016001889A1 (es) 2016-12-09
PT3323814T (pt) 2020-08-05
US20230085620A1 (en) 2023-03-23
NZ722063A (en) 2017-09-29
US12054465B2 (en) 2024-08-06
AU2019202675B2 (en) 2020-05-28
US11667615B2 (en) 2023-06-06
US11655222B2 (en) 2023-05-23
LT3323814T (lt) 2020-10-26
NZ734768A (en) 2022-09-30
PH12016501439B1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
PE20161218A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
DOP2019000010A (es) Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo
UY35243A (es) Inhibidores de fosfatidilinositol 3-cinasa
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
TN2014000033A1 (fr) Indazoles
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
JOP20130256B1 (ar) مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
MX394356B (es) Métodos y composiciones para tratar hiperhidrosis.
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201790088A1 (ru) Ингибиторы syk
PE20160194A1 (es) Composiciones y metodos para tratar anemia
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
PE20151666A1 (es) Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
PE20161432A1 (es) Compuestos y composiciones para inducir condrogenesis
EA201391337A1 (ru) Ингибиторы hsp90
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2014007878A (es) Formulaciones de (+) - 2 - [1 - (3 - etoxi - 4 - metoxi - fenil) - 2 - metansulfonil - etil] - 4 - acetil aminoisoindolin - 1, 3 - diona.
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
AR084144A1 (es) Compuestos y metodos para restaurar la piel
PE20142337A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
MX2021009909A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
UY31824A (es) Nuevos compuestos